Tian et al., 2013 - Google Patents
Alternative immunomodulatory strategies for xenotransplantation: CD80/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survivalTian et al., 2013
View HTML- Document ID
- 1391539377853575647
- Author
- Tian M
- Lv Y
- Zhai C
- Zhu H
- Yu L
- Wang B
- Publication year
- Publication venue
- PloS one
External Links
Snippet
Background Xenotransplantation is a promising approach to circumventing the current organ shortage. However, T-cell-dependent anti-xenoresponses are a major challenge to successful xenografts. Given the advantages of the use of CTLA4-Ig in the survival of …
- 230000004083 survival 0 title abstract description 35
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finck et al. | Engineered cellular immunotherapies in cancer and beyond | |
| Tian et al. | Alternative immunomodulatory strategies for xenotransplantation: CD80/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survival | |
| JP6818720B6 (en) | Methods for Inducing Partial Apoptosis Using Caspase Polypeptides | |
| Fändrich et al. | Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning | |
| Ito et al. | CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway | |
| Teague et al. | Immune evasion in acute myeloid leukemia: current concepts and future directions | |
| EP3234145B1 (en) | Methods for controlled activation or elimination of therapeutic cells | |
| EP2967081B1 (en) | Modified caspase polypeptides and uses thereof | |
| JP2022548523A (en) | Combination of cancer therapy and cytokine control therapy for cancer treatment | |
| Belz et al. | CD36 is differentially expressed by CD8+ splenic dendritic cells but is not required for cross-presentation in vivo | |
| JP2018501786A (en) | Controlled elimination of therapeutic cells | |
| Bose et al. | Cutting edge: perforin down-regulates CD4 and CD8 T cell-mediated immune responses to a transplanted organ | |
| US20170101624A1 (en) | Methods of enhancing t-cell longevity and uses thereof | |
| Grazia et al. | A two-step model of acute CD4 T-cell mediated cardiac allograft rejection | |
| Gorczynski et al. | Long-term tolerance and skin allograft survival in CD200tg mice after autologous marrow transplantation | |
| US20240122986A1 (en) | Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy | |
| Hosny et al. | 3′ UTR enhances hCD47 cell surface expression, self‐signal function, and reduces ER stress in porcine fibroblasts | |
| Cowan | Transgenic pigs for islet xenotransplantation | |
| JP7334249B2 (en) | Early apoptotic cells for use in treating sepsis | |
| Chen et al. | Hypodermin A improves survival of skin allografts | |
| Sen | Targeting Siglecs on Recipient Antigenpresenting Cells With Sialic Acid-Modified Alloantigen to Promote Transplantation Tolerance | |
| Ewing | Augmenting the graft-versus-leukaemia effect of allogeneic non-myeloablative transplantation | |
| Borenstein et al. | Induction of xenogeneic neonatal tolerance to transgenic human leukocyte antigen class I grafts | |
| HK40016843A (en) | Methods for inducing partial apoptosis using caspase polypeptides | |
| Zhai et al. | Alloreactive memory T cells in transplantation tolerance |